Veru opened lower at $2.10, compared with its previous close of $2.14. In the last trading session, the stock traded between $2.08 and $2.15. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Veru is now worth
$ 2.37
Resulting in a loss of
$ 97.63 (97.63%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 1 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-0.02 (-0.93%)
Day High
$2.15
Day Low
$2.08
Day Open
$2.10
Prev Close
$2.14
Volume
72,163
1W Return
-3.37%
1M Return
-11.74%
3M Return
-23.69%
6M Return
-4.07%
1Y Return
-19.08%
Fundamentals
Market Cap ($ Mn)
36
PE Ratio
-
PB Ratio
1.58
PEG Ratio
-
ROE
-68.98%
ROCE
-51.66%
EPS (TTM)
$-0.41
Investment Returns
1 Week
-3.37%
1 Month
-11.74%
3 Months
-23.69%
6 Months
-4.07%
9 Months
-7.83%
Financials
Quarterly
All values in $ Mn
0.0
Mar 25
0.0
Jun 25
0.0
Sep 25
0.0
Dec 25
0.0
Mar 26
0.0
Jun 26
Updates
9Nov
Veru to present Phase 2b QUALITY study analysis at ObesityWeek 2026
Veru Inc. will present post hoc analysis from Phase 2b QUALITY study at ObesityWeek 2026. Presentation covers physical function in patients aged 65+ with obesity on GLP-1 RA. Event scheduled for November 14-17, 2026, in Washington DC. Chief Scientific Officer Gary Barnette to deliver the podium presentation.
3 days ago
8Sep
Veru advances sabizabulin for pancreatic cancer after preclinical data
Veru advances sabizabulin into Phase 2 trial for metastatic pancreatic cancer. Preclinical data shows IC50 of 18.2 nM in daraxonrasib-resistant cell lines. Company redirects resources from cardiovascular disease program to oncology. Enobosarm Phase 2b obesity trial fully enrolled with 239 patients.
2mo ago
10Aug
Veru Q3 Results: EPS beats estimates, losses narrow 40% YoY
Veru delivered better-than-expected Q3 results with an EPS of $(0.30), beating the $(0.32) estimate. This marks a 40% YoY improvement from the $(0.50) loss seen in the previous year's quarter, indicating narrowing deficits.
3mo ago
4Aug
Veru Secures Patent Allowance for Enobosarm-Semaglutide Combination Therapy
Veru Inc. secured a USPTO Notice of Allowance for a patent covering enobosarm combined with semaglutide for quality weight loss. The patent, expiring in 2044, protects methods for preserving lean mass and preventing weight rebound. This supports Veru's Phase 2b PLATEAU trial, with interim data expected in Q1 2027.
3mo ago
27Jul
Veru Inc. completes Phase 2b PLATEAU trial enrollment for obesity drug
Veru Inc. completed enrollment in the Phase 2b PLATEAU trial for oral enobosarm 3 mg in older adults with obesity starting semaglutide. The ~200-patient study evaluates weight, muscle, and bone outcomes. Interim data due Q1 2027; final topline data expected Q4 2027.
3mo ago
3Jul
Veru announces $21.8M sales ATM program with Oppenheimer, Canaccord
Veru announced a $21.8M sales ATM program with Oppenheimer and Canaccord.
